-
The Food and Drug Administration ordered the closure of a warehouse inside the Jolly Plastic Industrial Park in Plaridel, Bulacan
-
TSQB Tolling and Manufacturing Corporation warehouse was sealed after counterfeit drugs were found
-
The inspection on February 20 was part of FDA’s nationwide compliance and enforcement drive
-
Warehouses inspected serve as distribution hubs supplying products to major e-commerce platforms, including Shopee, Lazada, and TikTok Shop
-
Inspection covered storage conditions, cold chain management, product registration, licensing compliance, and documentation for traceability
-
FDA director general Paolo Teston emphasized that enforcement must extend to distribution hubs supporting digital commerce
The Food and Drug Administration (FDA) ordered the closure of a warehouse inside the Jolly Plastic Industrial Park in Plaridel, Bulacan following the discovery of counterfeit drugs regulatory violations during a routine inspection.
The inspection was conducted on February 20, 2026, led by FDA director general Paolo Teston as part of the agency’s nationwide compliance and enforcement drive.
FDA sealed the warehouse of TSQB Tolling and Manufacturing Corporation for violations of Republic Act (RA) No. 8203, the Counterfeit Drugs Act, and RA No. 3720, otherwise known as the Food, Drugs, and Cosmetics Act, as amended by Executive Order No. 175 and Republic Act No. 9711.
The inspection also covered connected warehouses, with regulators verifying compliance with licensing and registration requirements prior to and during the enforcement activity.
Authorities said the warehouses serve as key distribution hubs supplying products to various retailers, including major e-commerce platforms such as Shopee, Lazada, and TikTok Shop. As critical control points in the supply chain, any compliance lapse at this level may directly compromise product safety before items reach consumers, FDA said in a news release.
The operation focused on assessing proper storage conditions, cold chain management for temperature-sensitive products, product registration status, licensing compliance, and documentation to ensure full traceability of food, drugs, medical devices, and other regulated health products. Distribution practices affecting both physical retail outlets and online marketplaces were given particular scrutiny.
Teston stressed that enforcement must extend beyond retail storefronts and cover distribution facilities that support digital commerce.
“Establisments found in violation of FDA laws and regulations will face immediate regulatory action, including seizure of products, suspension or revocation of licenses, closure of warehouses, and the filing of administrative and legal cases,” he said.
He added that regulatory oversight applies uniformly to all covered establishments.
“Compliance is mandatory for all establishments, regardless of size or location. The FDA will continue conducting both coordinated and unannounced inspections nationwide to ensure the integrity of the health product supply chain and protect consumers from unsafe products,” he added.
The agency reiterated its commitment to ensuring that all health products circulating in the market, whether sold in physical stores or through digital platforms, meet established standards of safety, quality, and compliance.
READ: Royal Cargo Calamba facility gets FDA licenses
